How the new rule is affecting healthcare orgs.
A new EPA rule on hazardous waste pharmaceuticals has healthcare executives rethinking their plan to dispose of drugs and hazardous waste.
Among other things, these new regulations in the final rule prohibit the disposal of hazardous waste pharmaceuticals down the drain and eliminates the dual regulation of RCRA hazardous waste pharmaceuticals that are also Drug Enforcement Administration (DEA) controlled substances. The new rules also maintains the household hazardous waste exemption for pharmaceuticals collected during pharmaceutical take-back programs and events, while ensuring their proper disposal.
“Sewering or flushing unused, hazardous medications can be harmful to the environment,” says John Holaday, PhD, CEO at DisposeRx, Inc., an at-home medication disposal solution company located in Sanford, North Carolina.
“Healthcare facilities-hospitals, pharmacies, nursing and long-term care facilities-are greatly impacted by this ruling, and as a result, their executives now must change their strategic approach to disposal of drugs and hazardous waste,” Holaday says.
Healthcare executives should take this as an opportunity to educate stakeholders about the risks associated with the storage and disposal of unused medications-whether that is an individual patient who has a leftover prescription at home, or health systems dealing with large volumes of hazardous medications, according to Holaday.
Related: Six Ways To Effectively Manage Pain During An Opioid Epidemic
“The common viewpoint for decades was that flushing and sewering were suitable ways to discard of hazardous medications, and now we know better and are aware of the profound environmental implications,” he says. “By immediately and appropriately discarding leftover medications-no matter the volume-we are protecting our waterways; and we are protecting our families from other potential tragedies, including accidental poisonings, diversion, addiction and even death.”
According to Holaday, there are three things healthcare executives should know about the new rule:
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More